 | • レポートコード：MRC2Q12-19364 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、114ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| コロナ禍により、原発性免疫不全治療薬の世界市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に原発性免疫不全治療薬のグローバル市場のxxx％を占める「サイトカイン」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「病院」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。 原発性免疫不全治療薬の中国市場規模は2021年にUS$xxxと分析されており、アメリカとヨーロッパの市場規模はそれぞれUS$xxxとUS$xxxです。アメリカの割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの原発性免疫不全治療薬市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。 原発性免疫不全治療薬のグローバル主要プレイヤーには、ADMA Biologics, Inc.、CSL Behring, LLC、Octapharma、Takeda Pharmaceutical Company、Grifols Biologicals, Inc.、Baxter、Kedrion Biopharma、BPL Inc.、Pharming Group、Shire、Chengdu Rongsheng Pharmaceutical Co., Ltdなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 原発性免疫不全治療薬市場は、種類と用途によって区分されます。世界の原発性免疫不全治療薬市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。 【種類別セグメント】 サイトカイン、抗サイトカイン抗体、シグナル分子阻害剤 【用途別セグメント】 病院、専門クリニック、その他 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 原発性免疫不全治療薬製品概要 - 種類別市場（サイトカイン、抗サイトカイン抗体、シグナル分子阻害剤） - 用途別市場（病院、専門クリニック、その他） - 調査の目的 ・エグゼクティブサマリー - 世界の原発性免疫不全治療薬販売量予測2017-2028 - 世界の原発性免疫不全治療薬売上予測2017-2028 - 原発性免疫不全治療薬の地域別販売量 - 原発性免疫不全治療薬の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別原発性免疫不全治療薬販売量 - 主要メーカー別原発性免疫不全治療薬売上 - 主要メーカー別原発性免疫不全治療薬価格 - 競争状況の分析 - 企業M&A動向 ・種類別市場規模（サイトカイン、抗サイトカイン抗体、シグナル分子阻害剤） - 原発性免疫不全治療薬の種類別販売量 - 原発性免疫不全治療薬の種類別売上 - 原発性免疫不全治療薬の種類別価格 ・用途別市場規模（病院、専門クリニック、その他） - 原発性免疫不全治療薬の用途別販売量 - 原発性免疫不全治療薬の用途別売上 - 原発性免疫不全治療薬の用途別価格 ・北米市場 - 北米の原発性免疫不全治療薬市場規模（種類別、用途別） - 主要国別の原発性免疫不全治療薬市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの原発性免疫不全治療薬市場規模（種類別、用途別） - 主要国別の原発性免疫不全治療薬市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の原発性免疫不全治療薬市場規模（種類別、用途別） - 主要国別の原発性免疫不全治療薬市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の原発性免疫不全治療薬市場規模（種類別、用途別） - 主要国別の原発性免疫不全治療薬市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの原発性免疫不全治療薬市場規模（種類別、用途別） - 主要国別の原発性免疫不全治療薬市場規模（トルコ、サウジアラビア） ・企業情報 ADMA Biologics, Inc.、CSL Behring, LLC、Octapharma、Takeda Pharmaceutical Company、Grifols Biologicals, Inc.、Baxter、Kedrion Biopharma、BPL Inc.、Pharming Group、Shire、Chengdu Rongsheng Pharmaceutical Co., Ltd ・産業チェーン及び販売チャネル分析 - 原発性免疫不全治療薬の産業チェーン分析 - 原発性免疫不全治療薬の原材料 - 原発性免疫不全治療薬の生産プロセス - 原発性免疫不全治療薬の販売及びマーケティング - 原発性免疫不全治療薬の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 原発性免疫不全治療薬の産業動向 - 原発性免疫不全治療薬のマーケットドライバー - 原発性免疫不全治療薬の課題 - 原発性免疫不全治療薬の阻害要因 ・主な調査結果 |
Drugs for the treatment of primary immunodeficiency diseases
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Product Name estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Primary Immunodeficiency Drugs is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Primary Immunodeficiency Drugs is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Primary Immunodeficiency Drugs is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key manufacturers of Primary Immunodeficiency Drugs include ADMA Biologics, Inc., CSL Behring, LLC, Octapharma, Takeda Pharmaceutical Company, Grifols Biologicals, Inc., Baxter, Kedrion Biopharma, BPL Inc. and Pharming Group, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, sales, revenue, price and gross margin. Major producers’ production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Primary Immunodeficiency Drugs manufacturers, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Primary Immunodeficiency Drugs market. Further, it explains the major drivers and regional dynamics of the global Primary Immunodeficiency Drugs market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable sales, revenue, price, market share and rank data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
ADMA Biologics, Inc.
CSL Behring, LLC
Octapharma
Takeda Pharmaceutical Company
Grifols Biologicals, Inc.
Baxter
Kedrion Biopharma
BPL Inc.
Pharming Group
Shire
Chengdu Rongsheng Pharmaceutical Co., Ltd
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides sales, revenue and average price forecast data by type and by application segments based on sales, price, and value for the period 2017-2028.
Primary Immunodeficiency Drugs Segment by Type
Cytokines
Anti Cytokine Antibodies
Signal Molecule Inhibitor
Primary Immunodeficiency Drugs Segment by Application
Hospital
Specialist Clinic
Othere
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value and sales data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Primary Immunodeficiency Drugs market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Primary Immunodeficiency Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Primary Immunodeficiency Drugs, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Primary Immunodeficiency Drugs, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Primary Immunodeficiency Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2017 to 2022. Identification of the major stakeholders in the global Primary Immunodeficiency Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2017 to 2028. Evaluation and forecast the market size for Primary Immunodeficiency Drugs sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including ADMA Biologics, Inc., CSL Behring, LLC, Octapharma, Takeda Pharmaceutical Company, Grifols Biologicals, Inc., Baxter, Kedrion Biopharma, BPL Inc. and Pharming Group, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Primary Immunodeficiency Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Primary Immunodeficiency Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, sales and revenue for each segment.
Chapter 7: Europe by type, by application and by country, sales and revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country, sales and revenue for each segment.
Chapter 9: Latin America by type, by application and by country, sales and revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, sales and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Primary Immunodeficiency Drugs sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
1 Study Coverage
1.1 Primary Immunodeficiency Drugs Product Introduction
1.2 Market by Type
1.2.1 Global Primary Immunodeficiency Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Cytokines
1.2.3 Anti Cytokine Antibodies
1.2.4 Signal Molecule Inhibitor
1.3 Market by Application
1.3.1 Global Primary Immunodeficiency Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Specialist Clinic
1.3.4 Othere
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Primary Immunodeficiency Drugs Sales Estimates and Forecasts 2017-2028
2.2 Global Primary Immunodeficiency Drugs Revenue Estimates and Forecasts 2017-2028
2.3 Global Primary Immunodeficiency Drugs Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Primary Immunodeficiency Drugs Sales by Region
2.4.1 Global Primary Immunodeficiency Drugs Sales by Region (2017-2022)
2.4.2 Global Sales Primary Immunodeficiency Drugs by Region (2023-2028)
2.5 Global Primary Immunodeficiency Drugs Revenue by Region
2.5.1 Global Primary Immunodeficiency Drugs Revenue by Region (2017-2022)
2.5.2 Global Primary Immunodeficiency Drugs Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Primary Immunodeficiency Drugs Sales by Manufacturers
3.1.1 Global Top Primary Immunodeficiency Drugs Manufacturers by Sales (2017-2022)
3.1.2 Global Primary Immunodeficiency Drugs Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Primary Immunodeficiency Drugs in 2021
3.2 Global Primary Immunodeficiency Drugs Revenue by Manufacturers
3.2.1 Global Primary Immunodeficiency Drugs Revenue by Manufacturers (2017-2022)
3.2.2 Global Primary Immunodeficiency Drugs Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Primary Immunodeficiency Drugs Revenue in 2021
3.3 Global Primary Immunodeficiency Drugs Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Primary Immunodeficiency Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Primary Immunodeficiency Drugs Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Primary Immunodeficiency Drugs Sales by Type
4.1.1 Global Primary Immunodeficiency Drugs Historical Sales by Type (2017-2022)
4.1.2 Global Primary Immunodeficiency Drugs Forecasted Sales by Type (2023-2028)
4.1.3 Global Primary Immunodeficiency Drugs Sales Market Share by Type (2017-2028)
4.2 Global Primary Immunodeficiency Drugs Revenue by Type
4.2.1 Global Primary Immunodeficiency Drugs Historical Revenue by Type (2017-2022)
4.2.2 Global Primary Immunodeficiency Drugs Forecasted Revenue by Type (2023-2028)
4.2.3 Global Primary Immunodeficiency Drugs Revenue Market Share by Type (2017-2028)
4.3 Global Primary Immunodeficiency Drugs Price by Type
4.3.1 Global Primary Immunodeficiency Drugs Price by Type (2017-2022)
4.3.2 Global Primary Immunodeficiency Drugs Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Primary Immunodeficiency Drugs Sales by Application
5.1.1 Global Primary Immunodeficiency Drugs Historical Sales by Application (2017-2022)
5.1.2 Global Primary Immunodeficiency Drugs Forecasted Sales by Application (2023-2028)
5.1.3 Global Primary Immunodeficiency Drugs Sales Market Share by Application (2017-2028)
5.2 Global Primary Immunodeficiency Drugs Revenue by Application
5.2.1 Global Primary Immunodeficiency Drugs Historical Revenue by Application (2017-2022)
5.2.2 Global Primary Immunodeficiency Drugs Forecasted Revenue by Application (2023-2028)
5.2.3 Global Primary Immunodeficiency Drugs Revenue Market Share by Application (2017-2028)
5.3 Global Primary Immunodeficiency Drugs Price by Application
5.3.1 Global Primary Immunodeficiency Drugs Price by Application (2017-2022)
5.3.2 Global Primary Immunodeficiency Drugs Price Forecast by Application (2023-2028)
6 North America
6.1 North America Primary Immunodeficiency Drugs Market Size by Type
6.1.1 North America Primary Immunodeficiency Drugs Sales by Type (2017-2028)
6.1.2 North America Primary Immunodeficiency Drugs Revenue by Type (2017-2028)
6.2 North America Primary Immunodeficiency Drugs Market Size by Application
6.2.1 North America Primary Immunodeficiency Drugs Sales by Application (2017-2028)
6.2.2 North America Primary Immunodeficiency Drugs Revenue by Application (2017-2028)
6.3 North America Primary Immunodeficiency Drugs Market Size by Country
6.3.1 North America Primary Immunodeficiency Drugs Sales by Country (2017-2028)
6.3.2 North America Primary Immunodeficiency Drugs Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Primary Immunodeficiency Drugs Market Size by Type
7.1.1 Europe Primary Immunodeficiency Drugs Sales by Type (2017-2028)
7.1.2 Europe Primary Immunodeficiency Drugs Revenue by Type (2017-2028)
7.2 Europe Primary Immunodeficiency Drugs Market Size by Application
7.2.1 Europe Primary Immunodeficiency Drugs Sales by Application (2017-2028)
7.2.2 Europe Primary Immunodeficiency Drugs Revenue by Application (2017-2028)
7.3 Europe Primary Immunodeficiency Drugs Market Size by Country
7.3.1 Europe Primary Immunodeficiency Drugs Sales by Country (2017-2028)
7.3.2 Europe Primary Immunodeficiency Drugs Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Primary Immunodeficiency Drugs Market Size by Type
8.1.1 Asia Pacific Primary Immunodeficiency Drugs Sales by Type (2017-2028)
8.1.2 Asia Pacific Primary Immunodeficiency Drugs Revenue by Type (2017-2028)
8.2 Asia Pacific Primary Immunodeficiency Drugs Market Size by Application
8.2.1 Asia Pacific Primary Immunodeficiency Drugs Sales by Application (2017-2028)
8.2.2 Asia Pacific Primary Immunodeficiency Drugs Revenue by Application (2017-2028)
8.3 Asia Pacific Primary Immunodeficiency Drugs Market Size by Region
8.3.1 Asia Pacific Primary Immunodeficiency Drugs Sales by Region (2017-2028)
8.3.2 Asia Pacific Primary Immunodeficiency Drugs Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Primary Immunodeficiency Drugs Market Size by Type
9.1.1 Latin America Primary Immunodeficiency Drugs Sales by Type (2017-2028)
9.1.2 Latin America Primary Immunodeficiency Drugs Revenue by Type (2017-2028)
9.2 Latin America Primary Immunodeficiency Drugs Market Size by Application
9.2.1 Latin America Primary Immunodeficiency Drugs Sales by Application (2017-2028)
9.2.2 Latin America Primary Immunodeficiency Drugs Revenue by Application (2017-2028)
9.3 Latin America Primary Immunodeficiency Drugs Market Size by Country
9.3.1 Latin America Primary Immunodeficiency Drugs Sales by Country (2017-2028)
9.3.2 Latin America Primary Immunodeficiency Drugs Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
9.3.6 Colombia
10 Middle East and Africa
10.1 Middle East and Africa Primary Immunodeficiency Drugs Market Size by Type
10.1.1 Middle East and Africa Primary Immunodeficiency Drugs Sales by Type (2017-2028)
10.1.2 Middle East and Africa Primary Immunodeficiency Drugs Revenue by Type (2017-2028)
10.2 Middle East and Africa Primary Immunodeficiency Drugs Market Size by Application
10.2.1 Middle East and Africa Primary Immunodeficiency Drugs Sales by Application (2017-2028)
10.2.2 Middle East and Africa Primary Immunodeficiency Drugs Revenue by Application (2017-2028)
10.3 Middle East and Africa Primary Immunodeficiency Drugs Market Size by Country
10.3.1 Middle East and Africa Primary Immunodeficiency Drugs Sales by Country (2017-2028)
10.3.2 Middle East and Africa Primary Immunodeficiency Drugs Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 ADMA Biologics, Inc.
11.1.1 ADMA Biologics, Inc. Corporation Information
11.1.2 ADMA Biologics, Inc. Overview
11.1.3 ADMA Biologics, Inc. Primary Immunodeficiency Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 ADMA Biologics, Inc. Primary Immunodeficiency Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 ADMA Biologics, Inc. Recent Developments
11.2 CSL Behring, LLC
11.2.1 CSL Behring, LLC Corporation Information
11.2.2 CSL Behring, LLC Overview
11.2.3 CSL Behring, LLC Primary Immunodeficiency Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 CSL Behring, LLC Primary Immunodeficiency Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 CSL Behring, LLC Recent Developments
11.3 Octapharma
11.3.1 Octapharma Corporation Information
11.3.2 Octapharma Overview
11.3.3 Octapharma Primary Immunodeficiency Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Octapharma Primary Immunodeficiency Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Octapharma Recent Developments
11.4 Takeda Pharmaceutical Company
11.4.1 Takeda Pharmaceutical Company Corporation Information
11.4.2 Takeda Pharmaceutical Company Overview
11.4.3 Takeda Pharmaceutical Company Primary Immunodeficiency Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Takeda Pharmaceutical Company Primary Immunodeficiency Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Takeda Pharmaceutical Company Recent Developments
11.5 Grifols Biologicals, Inc.
11.5.1 Grifols Biologicals, Inc. Corporation Information
11.5.2 Grifols Biologicals, Inc. Overview
11.5.3 Grifols Biologicals, Inc. Primary Immunodeficiency Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Grifols Biologicals, Inc. Primary Immunodeficiency Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Grifols Biologicals, Inc. Recent Developments
11.6 Baxter
11.6.1 Baxter Corporation Information
11.6.2 Baxter Overview
11.6.3 Baxter Primary Immunodeficiency Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Baxter Primary Immunodeficiency Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Baxter Recent Developments
11.7 Kedrion Biopharma
11.7.1 Kedrion Biopharma Corporation Information
11.7.2 Kedrion Biopharma Overview
11.7.3 Kedrion Biopharma Primary Immunodeficiency Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Kedrion Biopharma Primary Immunodeficiency Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Kedrion Biopharma Recent Developments
11.8 BPL Inc.
11.8.1 BPL Inc. Corporation Information
11.8.2 BPL Inc. Overview
11.8.3 BPL Inc. Primary Immunodeficiency Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 BPL Inc. Primary Immunodeficiency Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 BPL Inc. Recent Developments
11.9 Pharming Group
11.9.1 Pharming Group Corporation Information
11.9.2 Pharming Group Overview
11.9.3 Pharming Group Primary Immunodeficiency Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Pharming Group Primary Immunodeficiency Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Pharming Group Recent Developments
11.10 Shire
11.10.1 Shire Corporation Information
11.10.2 Shire Overview
11.10.3 Shire Primary Immunodeficiency Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Shire Primary Immunodeficiency Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Shire Recent Developments
11.11 Chengdu Rongsheng Pharmaceutical Co., Ltd
11.11.1 Chengdu Rongsheng Pharmaceutical Co., Ltd Corporation Information
11.11.2 Chengdu Rongsheng Pharmaceutical Co., Ltd Overview
11.11.3 Chengdu Rongsheng Pharmaceutical Co., Ltd Primary Immunodeficiency Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Chengdu Rongsheng Pharmaceutical Co., Ltd Primary Immunodeficiency Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Chengdu Rongsheng Pharmaceutical Co., Ltd Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Primary Immunodeficiency Drugs Industry Chain Analysis
12.2 Primary Immunodeficiency Drugs Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Primary Immunodeficiency Drugs Production Mode & Process
12.4 Primary Immunodeficiency Drugs Sales and Marketing
12.4.1 Primary Immunodeficiency Drugs Sales Channels
12.4.2 Primary Immunodeficiency Drugs Distributors
12.5 Primary Immunodeficiency Drugs Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Primary Immunodeficiency Drugs Industry Trends
13.2 Primary Immunodeficiency Drugs Market Drivers
13.3 Primary Immunodeficiency Drugs Market Challenges
13.4 Primary Immunodeficiency Drugs Market Restraints
14 Key Findings in The Global Primary Immunodeficiency Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
Table 1. Global Primary Immunodeficiency Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Cytokines
Table 3. Major Manufacturers of Anti Cytokine Antibodies
Table 4. Major Manufacturers of Signal Molecule Inhibitor
Table 5. Global Primary Immunodeficiency Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 6. Global Primary Immunodeficiency Drugs Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 7. Global Primary Immunodeficiency Drugs Sales by Region (2017-2022) & (K Units)
Table 8. Global Primary Immunodeficiency Drugs Sales Market Share by Region (2017-2022)
Table 9. Global Primary Immunodeficiency Drugs Sales by Region (2023-2028) & (K Units)
Table 10. Global Primary Immunodeficiency Drugs Sales Market Share by Region (2023-2028)
Table 11. Global Primary Immunodeficiency Drugs Revenue by Region (2017-2022) & (US$ Million)
Table 12. Global Primary Immunodeficiency Drugs Revenue Market Share by Region (2017-2022)
Table 13. Global Primary Immunodeficiency Drugs Revenue by Region (2023-2028) & (US$ Million)
Table 14. Global Primary Immunodeficiency Drugs Revenue Market Share by Region (2023-2028)
Table 15. Global Primary Immunodeficiency Drugs Sales by Manufacturers (2017-2022) & (K Units)
Table 16. Global Primary Immunodeficiency Drugs Sales Share by Manufacturers (2017-2022)
Table 17. Global Primary Immunodeficiency Drugs Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 18. Global Primary Immunodeficiency Drugs Revenue Share by Manufacturers (2017-2022)
Table 19. Primary Immunodeficiency Drugs Price by Manufacturers (2017-2022) &(US$/Unit)
Table 20. Global Primary Immunodeficiency Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 21. Global Primary Immunodeficiency Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Primary Immunodeficiency Drugs as of 2021)
Table 22. Primary Immunodeficiency Drugs Manufacturing Base Distribution and Headquarters
Table 23. Manufacturers Primary Immunodeficiency Drugs Product Offered
Table 24. Date of Manufacturers Enter into Primary Immunodeficiency Drugs Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Primary Immunodeficiency Drugs Sales by Type (2017-2022) & (K Units)
Table 27. Global Primary Immunodeficiency Drugs Sales by Type (2023-2028) & (K Units)
Table 28. Global Primary Immunodeficiency Drugs Sales Share by Type (2017-2022)
Table 29. Global Primary Immunodeficiency Drugs Sales Share by Type (2023-2028)
Table 30. Global Primary Immunodeficiency Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 31. Global Primary Immunodeficiency Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 32. Global Primary Immunodeficiency Drugs Revenue Share by Type (2017-2022)
Table 33. Global Primary Immunodeficiency Drugs Revenue Share by Type (2023-2028)
Table 34. Primary Immunodeficiency Drugs Price by Type (2017-2022) & (US$/Unit)
Table 35. Global Primary Immunodeficiency Drugs Price Forecast by Type (2023-2028) & (US$/Unit)
Table 36. Global Primary Immunodeficiency Drugs Sales by Application (2017-2022) & (K Units)
Table 37. Global Primary Immunodeficiency Drugs Sales by Application (2023-2028) & (K Units)
Table 38. Global Primary Immunodeficiency Drugs Sales Share by Application (2017-2022)
Table 39. Global Primary Immunodeficiency Drugs Sales Share by Application (2023-2028)
Table 40. Global Primary Immunodeficiency Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 41. Global Primary Immunodeficiency Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 42. Global Primary Immunodeficiency Drugs Revenue Share by Application (2017-2022)
Table 43. Global Primary Immunodeficiency Drugs Revenue Share by Application (2023-2028)
Table 44. Primary Immunodeficiency Drugs Price by Application (2017-2022) & (US$/Unit)
Table 45. Global Primary Immunodeficiency Drugs Price Forecast by Application (2023-2028) & (US$/Unit)
Table 46. North America Primary Immunodeficiency Drugs Sales by Type (2017-2022) & (K Units)
Table 47. North America Primary Immunodeficiency Drugs Sales by Type (2023-2028) & (K Units)
Table 48. North America Primary Immunodeficiency Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 49. North America Primary Immunodeficiency Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 50. North America Primary Immunodeficiency Drugs Sales by Application (2017-2022) & (K Units)
Table 51. North America Primary Immunodeficiency Drugs Sales by Application (2023-2028) & (K Units)
Table 52. North America Primary Immunodeficiency Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 53. North America Primary Immunodeficiency Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 54. North America Primary Immunodeficiency Drugs Sales by Country (2017-2022) & (K Units)
Table 55. North America Primary Immunodeficiency Drugs Sales by Country (2023-2028) & (K Units)
Table 56. North America Primary Immunodeficiency Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 57. North America Primary Immunodeficiency Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 58. Europe Primary Immunodeficiency Drugs Sales by Type (2017-2022) & (K Units)
Table 59. Europe Primary Immunodeficiency Drugs Sales by Type (2023-2028) & (K Units)
Table 60. Europe Primary Immunodeficiency Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 61. Europe Primary Immunodeficiency Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 62. Europe Primary Immunodeficiency Drugs Sales by Application (2017-2022) & (K Units)
Table 63. Europe Primary Immunodeficiency Drugs Sales by Application (2023-2028) & (K Units)
Table 64. Europe Primary Immunodeficiency Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 65. Europe Primary Immunodeficiency Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 66. Europe Primary Immunodeficiency Drugs Sales by Country (2017-2022) & (K Units)
Table 67. Europe Primary Immunodeficiency Drugs Sales by Country (2023-2028) & (K Units)
Table 68. Europe Primary Immunodeficiency Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 69. Europe Primary Immunodeficiency Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 70. Asia Pacific Primary Immunodeficiency Drugs Sales by Type (2017-2022) & (K Units)
Table 71. Asia Pacific Primary Immunodeficiency Drugs Sales by Type (2023-2028) & (K Units)
Table 72. Asia Pacific Primary Immunodeficiency Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 73. Asia Pacific Primary Immunodeficiency Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 74. Asia Pacific Primary Immunodeficiency Drugs Sales by Application (2017-2022) & (K Units)
Table 75. Asia Pacific Primary Immunodeficiency Drugs Sales by Application (2023-2028) & (K Units)
Table 76. Asia Pacific Primary Immunodeficiency Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 77. Asia Pacific Primary Immunodeficiency Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 78. Asia Pacific Primary Immunodeficiency Drugs Sales by Region (2017-2022) & (K Units)
Table 79. Asia Pacific Primary Immunodeficiency Drugs Sales by Region (2023-2028) & (K Units)
Table 80. Asia Pacific Primary Immunodeficiency Drugs Revenue by Region (2017-2022) & (US$ Million)
Table 81. Asia Pacific Primary Immunodeficiency Drugs Revenue by Region (2023-2028) & (US$ Million)
Table 82. Latin America Primary Immunodeficiency Drugs Sales by Type (2017-2022) & (K Units)
Table 83. Latin America Primary Immunodeficiency Drugs Sales by Type (2023-2028) & (K Units)
Table 84. Latin America Primary Immunodeficiency Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 85. Latin America Primary Immunodeficiency Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 86. Latin America Primary Immunodeficiency Drugs Sales by Application (2017-2022) & (K Units)
Table 87. Latin America Primary Immunodeficiency Drugs Sales by Application (2023-2028) & (K Units)
Table 88. Latin America Primary Immunodeficiency Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 89. Latin America Primary Immunodeficiency Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 90. Latin America Primary Immunodeficiency Drugs Sales by Country (2017-2022) & (K Units)
Table 91. Latin America Primary Immunodeficiency Drugs Sales by Country (2023-2028) & (K Units)
Table 92. Latin America Primary Immunodeficiency Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 93. Latin America Primary Immunodeficiency Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 94. Middle East and Africa Primary Immunodeficiency Drugs Sales by Type (2017-2022) & (K Units)
Table 95. Middle East and Africa Primary Immunodeficiency Drugs Sales by Type (2023-2028) & (K Units)
Table 96. Middle East and Africa Primary Immunodeficiency Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 97. Middle East and Africa Primary Immunodeficiency Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 98. Middle East and Africa Primary Immunodeficiency Drugs Sales by Application (2017-2022) & (K Units)
Table 99. Middle East and Africa Primary Immunodeficiency Drugs Sales by Application (2023-2028) & (K Units)
Table 100. Middle East and Africa Primary Immunodeficiency Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 101. Middle East and Africa Primary Immunodeficiency Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 102. Middle East and Africa Primary Immunodeficiency Drugs Sales by Country (2017-2022) & (K Units)
Table 103. Middle East and Africa Primary Immunodeficiency Drugs Sales by Country (2023-2028) & (K Units)
Table 104. Middle East and Africa Primary Immunodeficiency Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 105. Middle East and Africa Primary Immunodeficiency Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 106. ADMA Biologics, Inc. Corporation Information
Table 107. ADMA Biologics, Inc. Description and Major Businesses
Table 108. ADMA Biologics, Inc. Primary Immunodeficiency Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 109. ADMA Biologics, Inc. Primary Immunodeficiency Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 110. ADMA Biologics, Inc. Recent Developments
Table 111. CSL Behring, LLC Corporation Information
Table 112. CSL Behring, LLC Description and Major Businesses
Table 113. CSL Behring, LLC Primary Immunodeficiency Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 114. CSL Behring, LLC Primary Immunodeficiency Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 115. CSL Behring, LLC Recent Developments
Table 116. Octapharma Corporation Information
Table 117. Octapharma Description and Major Businesses
Table 118. Octapharma Primary Immunodeficiency Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 119. Octapharma Primary Immunodeficiency Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 120. Octapharma Recent Developments
Table 121. Takeda Pharmaceutical Company Corporation Information
Table 122. Takeda Pharmaceutical Company Description and Major Businesses
Table 123. Takeda Pharmaceutical Company Primary Immunodeficiency Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 124. Takeda Pharmaceutical Company Primary Immunodeficiency Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 125. Takeda Pharmaceutical Company Recent Developments
Table 126. Grifols Biologicals, Inc. Corporation Information
Table 127. Grifols Biologicals, Inc. Description and Major Businesses
Table 128. Grifols Biologicals, Inc. Primary Immunodeficiency Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 129. Grifols Biologicals, Inc. Primary Immunodeficiency Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 130. Grifols Biologicals, Inc. Recent Developments
Table 131. Baxter Corporation Information
Table 132. Baxter Description and Major Businesses
Table 133. Baxter Primary Immunodeficiency Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 134. Baxter Primary Immunodeficiency Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 135. Baxter Recent Developments
Table 136. Kedrion Biopharma Corporation Information
Table 137. Kedrion Biopharma Description and Major Businesses
Table 138. Kedrion Biopharma Primary Immunodeficiency Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 139. Kedrion Biopharma Primary Immunodeficiency Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 140. Kedrion Biopharma Recent Developments
Table 141. BPL Inc. Corporation Information
Table 142. BPL Inc. Description and Major Businesses
Table 143. BPL Inc. Primary Immunodeficiency Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 144. BPL Inc. Primary Immunodeficiency Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 145. BPL Inc. Recent Developments
Table 146. Pharming Group Corporation Information
Table 147. Pharming Group Description and Major Businesses
Table 148. Pharming Group Primary Immunodeficiency Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 149. Pharming Group Primary Immunodeficiency Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 150. Pharming Group Recent Developments
Table 151. Shire Corporation Information
Table 152. Shire Description and Major Businesses
Table 153. Shire Primary Immunodeficiency Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 154. Shire Primary Immunodeficiency Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 155. Shire Recent Developments
Table 156. Chengdu Rongsheng Pharmaceutical Co., Ltd Corporation Information
Table 157. Chengdu Rongsheng Pharmaceutical Co., Ltd Description and Major Businesses
Table 158. Chengdu Rongsheng Pharmaceutical Co., Ltd Primary Immunodeficiency Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 159. Chengdu Rongsheng Pharmaceutical Co., Ltd Primary Immunodeficiency Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 160. Chengdu Rongsheng Pharmaceutical Co., Ltd Recent Developments
Table 161. Key Raw Materials Lists
Table 162. Raw Materials Key Suppliers Lists
Table 163. Primary Immunodeficiency Drugs Distributors List
Table 164. Primary Immunodeficiency Drugs Customers List
Table 165. Primary Immunodeficiency Drugs Market Trends
Table 166. Primary Immunodeficiency Drugs Market Drivers
Table 167. Primary Immunodeficiency Drugs Market Challenges
Table 168. Primary Immunodeficiency Drugs Market Restraints
Table 169. Research Programs/Design for This Report
Table 170. Key Data Information from Secondary Sources
Table 171. Key Data Information from Primary Sources
List of Figures
Figure 1. Primary Immunodeficiency Drugs Product Picture
Figure 2. Global Primary Immunodeficiency Drugs Market Share by Type in 2021 & 2028
Figure 3. Cytokines Product Picture
Figure 4. Anti Cytokine Antibodies Product Picture
Figure 5. Signal Molecule Inhibitor Product Picture
Figure 6. Global Primary Immunodeficiency Drugs Market Share by Application in 2021 & 2028
Figure 7. Hospital
Figure 8. Specialist Clinic
Figure 9. Othere
Figure 10. Primary Immunodeficiency Drugs Report Years Considered
Figure 11. Global Primary Immunodeficiency Drugs Sales 2017-2028 (K Units)
Figure 12. Global Primary Immunodeficiency Drugs Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 13. Global Primary Immunodeficiency Drugs Revenue 2017-2028 (US$ Million)
Figure 14. Global Primary Immunodeficiency Drugs Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 15. Global Primary Immunodeficiency Drugs Sales Market Share by Region (2017-2022)
Figure 16. Global Primary Immunodeficiency Drugs Sales Market Share by Region (2023-2028)
Figure 17. North America Primary Immunodeficiency Drugs Sales YoY (2017-2028) & (K Units)
Figure 18. North America Primary Immunodeficiency Drugs Revenue YoY (2017-2028) & (US$ Million)
Figure 19. Europe Primary Immunodeficiency Drugs Sales YoY (2017-2028) & (K Units)
Figure 20. Europe Primary Immunodeficiency Drugs Revenue YoY (2017-2028) & (US$ Million)
Figure 21. Asia-Pacific Primary Immunodeficiency Drugs Sales YoY (2017-2028) & (K Units)
Figure 22. Asia-Pacific Primary Immunodeficiency Drugs Revenue YoY (2017-2028) & (US$ Million)
Figure 23. Latin America Primary Immunodeficiency Drugs Sales YoY (2017-2028) & (K Units)
Figure 24. Latin America Primary Immunodeficiency Drugs Revenue YoY (2017-2028) & (US$ Million)
Figure 25. Middle East & Africa Primary Immunodeficiency Drugs Sales YoY (2017-2028) & (K Units)
Figure 26. Middle East & Africa Primary Immunodeficiency Drugs Revenue YoY (2017-2028) & (US$ Million)
Figure 27. The Primary Immunodeficiency Drugs Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 28. The Top 5 and 10 Largest Manufacturers of Primary Immunodeficiency Drugs in the World: Market Share by Primary Immunodeficiency Drugs Revenue in 2021
Figure 29. Global Primary Immunodeficiency Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 30. Global Primary Immunodeficiency Drugs Sales Market Share by Type (2017-2028)
Figure 31. Global Primary Immunodeficiency Drugs Revenue Market Share by Type (2017-2028)
Figure 32. Global Primary Immunodeficiency Drugs Sales Market Share by Application (2017-2028)
Figure 33. Global Primary Immunodeficiency Drugs Revenue Market Share by Application (2017-2028)
Figure 34. North America Primary Immunodeficiency Drugs Sales Market Share by Type (2017-2028)
Figure 35. North America Primary Immunodeficiency Drugs Revenue Market Share by Type (2017-2028)
Figure 36. North America Primary Immunodeficiency Drugs Sales Market Share by Application (2017-2028)
Figure 37. North America Primary Immunodeficiency Drugs Revenue Market Share by Application (2017-2028)
Figure 38. North America Primary Immunodeficiency Drugs Sales Share by Country (2017-2028)
Figure 39. North America Primary Immunodeficiency Drugs Revenue Share by Country (2017-2028)
Figure 40. United States Primary Immunodeficiency Drugs Revenue (2017-2028) & (US$ Million)
Figure 41. Canada Primary Immunodeficiency Drugs Revenue (2017-2028) & (US$ Million)
Figure 42. Europe Primary Immunodeficiency Drugs Sales Market Share by Type (2017-2028)
Figure 43. Europe Primary Immunodeficiency Drugs Revenue Market Share by Type (2017-2028)
Figure 44. Europe Primary Immunodeficiency Drugs Sales Market Share by Application (2017-2028)
Figure 45. Europe Primary Immunodeficiency Drugs Revenue Market Share by Application (2017-2028)
Figure 46. Europe Primary Immunodeficiency Drugs Sales Share by Country (2017-2028)
Figure 47. Europe Primary Immunodeficiency Drugs Revenue Share by Country (2017-2028)
Figure 48. Germany Primary Immunodeficiency Drugs Revenue (2017-2028) & (US$ Million)
Figure 49. France Primary Immunodeficiency Drugs Revenue (2017-2028) & (US$ Million)
Figure 50. U.K. Primary Immunodeficiency Drugs Revenue (2017-2028) & (US$ Million)
Figure 51. Italy Primary Immunodeficiency Drugs Revenue (2017-2028) & (US$ Million)
Figure 52. Russia Primary Immunodeficiency Drugs Revenue (2017-2028) & (US$ Million)
Figure 53. Asia Pacific Primary Immunodeficiency Drugs Sales Market Share by Type (2017-2028)
Figure 54. Asia Pacific Primary Immunodeficiency Drugs Revenue Market Share by Type (2017-2028)
Figure 55. Asia Pacific Primary Immunodeficiency Drugs Sales Market Share by Application (2017-2028)
Figure 56. Asia Pacific Primary Immunodeficiency Drugs Revenue Market Share by Application (2017-2028)
Figure 57. Asia Pacific Primary Immunodeficiency Drugs Sales Share by Region (2017-2028)
Figure 58. Asia Pacific Primary Immunodeficiency Drugs Revenue Share by Region (2017-2028)
Figure 59. China Primary Immunodeficiency Drugs Revenue (2017-2028) & (US$ Million)
Figure 60. Japan Primary Immunodeficiency Drugs Revenue (2017-2028) & (US$ Million)
Figure 61. South Korea Primary Immunodeficiency Drugs Revenue (2017-2028) & (US$ Million)
Figure 62. India Primary Immunodeficiency Drugs Revenue (2017-2028) & (US$ Million)
Figure 63. Australia Primary Immunodeficiency Drugs Revenue (2017-2028) & (US$ Million)
Figure 64. China Taiwan Primary Immunodeficiency Drugs Revenue (2017-2028) & (US$ Million)
Figure 65. Indonesia Primary Immunodeficiency Drugs Revenue (2017-2028) & (US$ Million)
Figure 66. Thailand Primary Immunodeficiency Drugs Revenue (2017-2028) & (US$ Million)
Figure 67. Malaysia Primary Immunodeficiency Drugs Revenue (2017-2028) & (US$ Million)
Figure 68. Latin America Primary Immunodeficiency Drugs Sales Market Share by Type (2017-2028)
Figure 69. Latin America Primary Immunodeficiency Drugs Revenue Market Share by Type (2017-2028)
Figure 70. Latin America Primary Immunodeficiency Drugs Sales Market Share by Application (2017-2028)
Figure 71. Latin America Primary Immunodeficiency Drugs Revenue Market Share by Application (2017-2028)
Figure 72. Latin America Primary Immunodeficiency Drugs Sales Share by Country (2017-2028)
Figure 73. Latin America Primary Immunodeficiency Drugs Revenue Share by Country (2017-2028)
Figure 74. Mexico Primary Immunodeficiency Drugs Revenue (2017-2028) & (US$ Million)
Figure 75. Brazil Primary Immunodeficiency Drugs Revenue (2017-2028) & (US$ Million)
Figure 76. Argentina Primary Immunodeficiency Drugs Revenue (2017-2028) & (US$ Million)
Figure 77. Colombia Primary Immunodeficiency Drugs Revenue (2017-2028) & (US$ Million)
Figure 78. Middle East and Africa Primary Immunodeficiency Drugs Sales Market Share by Type (2017-2028)
Figure 79. Middle East and Africa Primary Immunodeficiency Drugs Revenue Market Share by Type (2017-2028)
Figure 80. Middle East and Africa Primary Immunodeficiency Drugs Sales Market Share by Application (2017-2028)
Figure 81. Middle East and Africa Primary Immunodeficiency Drugs Revenue Market Share by Application (2017-2028)
Figure 82. Middle East and Africa Primary Immunodeficiency Drugs Sales Share by Country (2017-2028)
Figure 83. Middle East and Africa Primary Immunodeficiency Drugs Revenue Share by Country (2017-2028)
Figure 84. Turkey Primary Immunodeficiency Drugs Revenue (2017-2028) & (US$ Million)
Figure 85. Saudi Arabia Primary Immunodeficiency Drugs Revenue (2017-2028) & (US$ Million)
Figure 86. UAE Primary Immunodeficiency Drugs Revenue (2017-2028) & (US$ Million)
Figure 87. Primary Immunodeficiency Drugs Value Chain
Figure 88. Primary Immunodeficiency Drugs Production Process
Figure 89. Channels of Distribution
Figure 90. Distributors Profiles
Figure 91. Bottom-up and Top-down Approaches for This Report
Figure 92. Data Triangulation
Figure 93. Key Executives Interviewed